CBD-WHO Report 6 – 10 November 2017, Geneva

Cannabidiol (CBD) is one of the naturally occurring cannabinoids in hemp. This is a
terpene-phenolic compound containing twenty-one carbon atoms. It arises as a result of
decarboxylation of cannabidiol acid, but may also be obtained synthetically.

Under laboratory conditions, CBD can be converted into tetrahydrocannabinol (THC),
however, such tranfsormation does not appear to occur with CBD given to patients
during therapy.

In experimental models of cbd abuse potential, there seems to be little effect on
conditioned site selection or intracraniated autostimulation in rats. In animal
preference models for CBD substances did not displace THC. In the case of humans, CBD does not show
any effects indicating the potential for abuse or dependence.

Several clinical studies have demonstrated the efficacy of CBD in the treatment of epilepsy, one
Containing pure cannabidiol (Epidiolex®) is currently going through the third phase of clinical trials.
Preliminary evidence also suggests the effectiveness of CBD in treating several other ailments.

CBD products available online – such as oils, dietary supplements, gums, or
concentrated extracts are used unregulatedly in the treatment of multiple ailments.

CBD is generally well tolerated and has a good safety profile. Reported effects
may be the result of interactions with other medicines taken by patients.

Several countries have modified their regulations to allow cannabidiol as a medical product.

There is no evidence so far of recreational use of CBD or any problems
public health associated with the intake of pure CBD.